Xenogen IVIS-200 Bioluminescent Imaging System

描述（由申请人提供）：通过将人类疾病的复杂小鼠模型与生物发光报告系统相结合，在肿瘤学研究中使用小鼠模型的革命已经产生。优化用于量化生物发光信号的高灵敏度成像系统为研究人员提供了以高灵敏度和高通量真实的时间监测在活哺乳动物中发生的生物过程的机会。从这种分子成像方法中获得的信息通常无法从其他成像方式中获得，并且当前的商业成像系统使用简单且维护成本低廉。Fox Chase癌症中心（FCCC）的一些研究人员目前正在从事或正在开发需要使用最先进的生物发光成像（BLI）系统的动物模型。将对转基因发光动物或来源于在免疫受损宿主动物中生长的用发光基因转染的细胞系的肿瘤进行成像，以研究动物中响应于治疗的分子变化，检测小的转移性肿瘤，并在系列实验中跟踪肿瘤生长。这些实验将使用比传统的连续处死方法少得多的动物，并为我们提供了一个真实的时间测定靶基因表达的分子靶向治疗。BLI设备将补充我们现有的小动物MRI扫描仪（目前FCCC唯一可用的成像模式），收购该设备是我们创建多模式动物成像套件长期计划的合理下一步。项目相关性：该提案将提出广泛的临床前研究，包括结肠癌的化疗，前列腺癌中原发性和转移性肿瘤治疗的联合疗法的作用，蛋白质合成中断的作用，激素相互作用在乳腺癌中的作用，以及由于许多肿瘤类型表现出的不良血管系统而导致的肿瘤对治疗的耐药性现象。所获得的信息将指导研究人员正确使用正在研究的治疗或预防药物，并阐明特定分子事件在肿瘤形成和发展中的作用。

DESCRIPTION (provided by applicant): A revolution in the use of mouse models in oncology research has been created by combining sophisticated mouse models of human disease with bioluminescent reporter systems. Highly sensitive imaging systems optimized for quantifying the bioluminescent signals offer researchers the opportunity to monitor biological processes taking place in a living mammal in real time, with high sensitivity and high throughput. The information gained from this molecular imaging approach is generally unobtainable from other imaging modalities, and current commercial imaging systems are straightforward to use and inexpensive to maintain. A number of investigators at Fox Chase Cancer Center (FCCC) are currently engaged in, or are developing, animal models that will require access to a state-of-the-art bioluminescent imaging (BLI) system. Transgenic luminescent animals, or tumors derived from cell lines transfected with luminescent genes grown in immunocompromised host animals will be imaged to study molecular changes in animals in response to treatment, detect small metastatic tumors, and follow tumor growth in serial experiments. These experiments will use far fewer animals than traditional methods of serial sacrifice, and provide us with a real time assay of target gene expression for molecularly targeted therapies. BLI equipment will complement our existing small animal MRI scanner (currently the only imaging modality available at FCCC), and acquisition of this equipment is the logical next step in our long term plans to create a multi-modal animal imaging suite. Project Relevance: This proposal will present a broad range of preclinical research, including chemotherapy in colon cancer, the role of combination therapies for the treatment of primary and metastatic tumors in prostate cancer, the role of disruptions in protein synthesis, the role of hormone interactions in breast cancer, and the phenomenon of tumor resistance to therapy because of the poor vasculature exhibited by many tumor types. The information gained will guide researchers in the appropriate use of the therapeutic or preventive agents being studied, and elucidate the roles of specific molecular events in tumor formation and development.